引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 137次   下载 35 本文二维码信息
码上扫一扫!
利拉鲁肽联合枸橼酸氯米芬对多囊卵巢综合征伴胰岛素抵抗患者外周血T细胞亚群及氧化应激水平的影响
冷少华,王延洲,赵小兰
0
(陆军军医大学附属西南医院健康管理中心;陆军军医大学附属西南医院妇产科)
摘要:
【摘要】 目的 探讨利拉鲁肽联合枸橼酸氯米芬对多囊卵巢综合征伴胰岛素抵抗患者外周血T细胞亚群及氧化应激水平的影响。方法 选自医院2014年12月~2016年12月期间收治的多囊卵巢综合征(PCOS)伴胰岛素抵抗(IR)患者92例,按照随机表法分为观察组46例与对照组46例。观察组采用利拉鲁肽联合枸橼酸氯米芬治疗,对照组仅采用枸橼酸氯米芬治疗。两组疗程均为3个月经周期。结果 观察组治疗总有效率(8261%)高于对照组(6087%)(P<005);两组治疗后平均体重指数(BMI)和卵巢体积均有降低(P<005);观察组治疗后BMI和卵巢体积低于对照组(P<005)。两组治疗后LH、FSH和T水平均有降低(P<005);观察组治疗后LH、FSH和T水平低于对照组(P<005)。两组治疗后FINS和HOMAIR均有降低(P<005);观察组治疗后FINS和HOMAIR低于对照组(P<005);两组治疗后CD3+和CD4+/CD8+均有降低(P<005)。观察组治疗后CD3+和CD4+/CD8+低于对照组(P<005);两组治疗后MDA降低而SOD增加(P<005);观察组治疗后MDA低于对照组而SOD高于对照组(P<005)。两组不良反应发生率比较无统计学差异(P>005)。结论 利拉鲁肽联合枸橼酸氯米芬对多囊卵巢综合征伴胰岛素抵抗患者疗效明显,可显著改善患者外周血T淋巴细胞亚群和氧化应激,具有重要的临床应用价值。
关键词:  利拉鲁肽  枸橼酸氯米芬  多囊卵巢综合征  胰岛素抵抗  T淋巴细胞亚群  氧化应激
DOI:
基金项目:重庆市科技创新专项(csts2015shmszx120100)
Effects of liraglutide combined with clomiphene on peripheral blood T cell subsets and oxidative stress of patients with polycystic ovary syndrome and insulin resistance
LENG Shaohua,WANG Yanzhou,ZHAO Xiaolan
(Department of Health Management, Southwest Hospital of Army Military Medical University;Department of Gynaecology and Obstetrics, Southwest Hospital of Army Military Medical University)
Abstract:
【Abstract】 Objective To investigate the effects of liraglutide combined with clomiphene on peripheral blood T cell subsets and oxidative stress of patients with polycystic ovary syndrome (PCOS) and insulin resistance. Methods 92 patients with PCOS and insulin resistance in our hospital from December 2014 to December 2016 were divided into observation group (46 cases) and control group (46 cases). The observation group was treated with liraglutide combined with clomiphene citrate. The control group was treated with clomiphene citrate. Results The total efficiency of the observation group (8261%) was higher than the control group (6087%) (P<005). BMI and ovarian volume of the two groups decreased after treatment. BMI and ovarian volume of observation group after treatment were lower than that of the control group (t=65840, 115294, P<005). LH, FSH and T of the two groups reduced after treatment. LH, FSH and T levels after treatment in the observation group were lower than that of control group (t=58437, 70905, 70161, P<005). FINS and HOMAIR in two groups after decreased after treatment. FINS and HOMAIR after treatment of observation group were lower than that of the control group (t=76955, 78588, P<005). CD3+ and CD4+/C D8+ of the two groups decreased after treatment. CD3+ and CD4+/CD8+ after treatment of the observation group were lower than that of control group (t=77320, 59132, P<005). MDA in the observation group was lower than that of the control group and the SOD was higher than that of control group (t=93624, 66042, P<005). There was no significant difference in the incidence of adverse reactions between the two groups (P>005). Conclusion Liraglutide combined with clomiphene can get obvious curative effect on polycystic ovary syndrome with insulin resistance, significantly improve blood T lymphocyte subsets and oxidative stress of patients with polycystic ovary syndrome with insulin resistance.
Key words:  Liraglutide  Clomiphene citrate  Polycystic ovary syndrome  Insulin resistance  T lymphocyte subsets  Oxidative stress

用微信扫一扫

用微信扫一扫